[MRCB] YoY Cumulative Quarter Result on 31-Dec-2018 [#4]

Stock
[MRCB] MALAYSIAN RESOURCES CORPORATION BERHAD
Announcement Date
26-Feb-2019
Admission Sponsor
-
Sponsor
-
Financial Year
31-Dec-2018
Quarter
31-Dec-2018 [#4]
Profit Trend
QoQ- 35.31%
YoY- -39.63%
Quarter Report
Latest QR
Upcoming QR
MRCB's Result
MRCB's Financial Summary
View:
Show?
Cumulative Result
31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 31/12/16 31/12/15 CAGR
Revenue 1,448,450 1,199,484 1,319,393 1,870,705 2,823,651 2,408,072 1,696,727 -2.59%
PBT 61,303 -152,916 52,955 122,987 247,333 392,629 370,112 -25.87%
Tax -54,585 -22,950 -34,263 -20,332 -65,525 -73,532 -6,083 44.10%
NP 6,718 -175,866 18,692 102,655 181,808 319,097 364,029 -48.56%
-
NP to SH 15,834 -176,143 23,739 101,167 167,575 267,360 330,392 -39.70%
-
Tax Rate 89.04% - 64.70% 16.53% 26.49% 18.73% 1.64% -
Total Cost 1,441,732 1,375,350 1,300,701 1,768,050 2,641,843 2,088,975 1,332,698 1.31%
-
Net Worth 4,512,184 4,579,703 4,791,482 4,829,850 2,411,814 2,644,539 2,259,166 12.20%
Dividend
31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 31/12/16 31/12/15 CAGR
Div 44,675 44,120 44,120 76,838 38,369 53,278 44,647 0.01%
Div Payout % 282.15% 0.00% 185.86% 75.95% 22.90% 19.93% 13.51% -
Equity
31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 31/12/16 31/12/15 CAGR
Net Worth 4,512,184 4,579,703 4,791,482 4,829,850 2,411,814 2,644,539 2,259,166 12.20%
NOSH 4,467,509 4,412,046 4,412,046 4,395,052 4,386,746 1,937,391 1,785,902 16.49%
Ratio Analysis
31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 31/12/16 31/12/15 CAGR
NP Margin 0.46% -14.66% 1.42% 5.49% 6.44% 13.25% 21.45% -
ROE 0.35% -3.85% 0.50% 2.09% 6.95% 10.11% 14.62% -
Per Share
31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 31/12/16 31/12/15 CAGR
RPS 32.42 27.19 29.90 42.61 128.78 124.29 95.01 -16.39%
EPS 0.36 -3.99 0.54 2.30 6.56 13.80 18.50 -48.10%
DPS 1.00 1.00 1.00 1.75 1.75 2.75 2.50 -14.15%
NAPS 1.01 1.038 1.086 1.10 1.10 1.365 1.265 -3.67%
Adjusted Per Share Value based on latest NOSH - 4,395,052
31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 31/12/16 31/12/15 CAGR
RPS 32.70 27.08 29.79 42.23 63.75 54.36 38.31 -2.60%
EPS 0.36 -3.98 0.54 2.28 3.78 6.04 7.46 -39.63%
DPS 1.01 1.00 1.00 1.73 0.87 1.20 1.01 0.00%
NAPS 1.0187 1.0339 1.0817 1.0904 0.5445 0.597 0.51 12.21%
Price Multiplier on Financial Quarter End Date
31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 31/12/16 31/12/15 CAGR
Date 31/12/21 31/12/20 31/12/19 31/12/18 29/12/17 30/12/16 31/12/15 -
Price 0.355 0.475 0.73 0.615 1.12 1.33 1.28 -
P/RPS 1.09 1.75 2.44 1.44 0.87 1.07 1.35 -3.49%
P/EPS 100.16 -11.90 135.68 26.69 14.65 9.64 6.92 56.04%
EY 1.00 -8.40 0.74 3.75 6.82 10.38 14.45 -35.89%
DY 2.82 2.11 1.37 2.85 1.56 2.07 1.95 6.33%
P/NAPS 0.35 0.46 0.67 0.56 1.02 0.97 1.01 -16.17%
Price Multiplier on Announcement Date
31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 31/12/16 31/12/15 CAGR
Date 28/02/22 25/02/21 26/02/20 26/02/19 28/02/18 27/02/17 22/02/16 -
Price 0.355 0.415 0.66 0.80 1.08 1.43 1.21 -
P/RPS 1.09 1.53 2.21 1.88 0.84 1.15 1.27 -2.51%
P/EPS 100.16 -10.39 122.67 34.72 14.13 10.36 6.54 57.52%
EY 1.00 -9.62 0.82 2.88 7.08 9.65 15.29 -36.49%
DY 2.82 2.41 1.52 2.19 1.62 1.92 2.07 5.28%
P/NAPS 0.35 0.40 0.61 0.73 0.98 1.05 0.96 -15.46%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ ⃤ & YoY ⃤ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment